Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine

Nikolai Petrovsky

DOI: https://doi.org/10.1080/21645515.2024.2363016

2024-06-07

Human Vaccines & Immunotherapeutics

Abstract:Recombinant protein vaccines represent a well-established, reliable and safe approach for pandemic vaccination. SpikoGen® is a recombinant spike protein trimer manufactured in insect cells and formulated with Advax-CpG55.2 adjuvant. In murine, hamster, ferret and non-human primate studies, SpikoGen® consistently provided protection against a range of SARS-CoV-2 variants. A pivotal Phase 3 placebo-controlled efficacy trial involving 16,876 participants confirmed the ability of SpikoGen® to prevent infection and severe disease caused by the virulent Delta strain. SpikoGen® subsequently received a marketing authorization from the Iranian FDA in early October 2021 for prevention of COVID-19 in adults. Following a successful pediatric study, its approval was extended to children 5 years and older. Eight million doses of SpikoGen® have been delivered, and a next-generation booster version is currently in development. This highlights the benefits of adjuvanted protein-based approaches which should not overlook when vaccine platforms are being selected for future pandemics.

immunology,biotechnology & applied microbiology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the effectiveness and safety of the SpikoGen® vaccine in preventing SARS - CoV - 2 infection and transmission. Specifically, the paper explores the following issues:

1. **Clinical development and effectiveness of the vaccine**:
- SpikoGen® is a recombinant spike protein trimer vaccine combined with the Advax - CpG55.2 adjuvant.
- Verify its protective effect against different SARS - CoV - 2 variants through animal experiments (mice, hamsters, ferrets and non - human primates).
- In human clinical trials, evaluate its effectiveness in preventing symptomatic, PCR - confirmed SARS - CoV - 2 infection.

2. **Safety of the vaccine**:
- Conduct safety and tolerability evaluations in multiple species to ensure that there are no major adverse events.
- Through phase I, phase II and phase III clinical trials, verify its safety in humans, especially the degree and duration of common adverse reactions such as injection - site pain, fatigue and headache.

3. **Immunogenicity of the vaccine**:
- Study whether the SpikoGen® vaccine can induce strong humoral and cellular immune responses, including the production of neutralizing antibodies and T - cell responses.
- Compare the effects of different doses and vaccination regimens to determine the optimal immunization strategy.

4. **Cross - protection ability**:
- Explore the protective effect of the SpikoGen® vaccine against heterologous virus strains (such as Delta, Omicron and other variants).
- Verify whether the vaccine can still provide protection when the neutralizing antibody level is low, possibly by inducing non - neutralizing antibodies or T - cell responses.

5. **Ability to prevent virus transmission**:
- Through animal models, study whether the SpikoGen® vaccine can reduce nasal virus shedding, thereby preventing the virus from spreading from infected hosts to uninfected hosts.

6. **Comparison with other vaccines**:
- Compare SpikoGen® with other recombinant protein vaccines such as Novavax, and emphasize its uniqueness in using soluble secreted spike protein ECD and different adjuvants.
- Discuss the advantages and disadvantages of protein - based vaccines compared to mRNA and adenovirus - vector vaccines, especially in terms of cost, stability and long - term protection.

In summary, this paper aims to comprehensively evaluate the effectiveness, safety and potential advantages of the SpikoGen® vaccine as a recombinant protein vaccine in response to SARS - CoV - 2 and its variants.